# Green Thumb Industries (GTBIF) — Initiating Coverage

## 1. The Hook

There's a company doing $1.18 billion in revenue, generating $295 million in operating cash flow, and posting $114 million in GAAP net income — and virtually nobody on Wall Street covers it. Green Thumb Industries trades on the OTC market at $6.67 per share, about 60% below its 52-week high, with a market cap of roughly $1.5 billion. That gives it a price-to-earnings ratio of about 14 times — except those earnings are being taxed at 56%, not 21%. If Green Thumb paid taxes like a normal company, its net income would nearly double to over $200 million. At the current stock price, that implies a P/E under 8 times. The reason nobody covers this stock is the same reason its tax rate is 56%: cannabis is still a Schedule I substance under federal law.

## 2. Company Snapshot

Green Thumb Industries is a Chicago-based multi-state cannabis operator running 113 retail stores under the RISE brand across 14 states, backed by 20 manufacturing facilities. Founded by CEO Ben Kovler, the company reports in two segments: Retail (71% of net revenue) and Consumer Packaged Goods, or CPG (29%). Its brand portfolio — led by RYTHM (the number-one flower brand nationally), Dogwalkers (pre-rolls), and incredibles (edibles) — has positioned GTI as the most consistently profitable public cannabis company in the United States. The analysis here is based on Green Thumb's 10-K for fiscal year 2025, filed February 25, 2026.

## 3. The Financial Story

**Revenue: Slow and steady in a brutal industry.** Green Thumb grew revenue from $894 million in FY2021 to $1.175 billion in FY2025 — a compounded growth rate of about 7% per year through the worst cannabis downturn on record. That trajectory matters. While many peers saw revenue plateau or decline as wholesale prices collapsed and state-level competition intensified, GTI kept grinding upward. FY2025 revenue of $1.175 billion was up 3.4% year over year, driven by the September 2025 launch of adult-use sales in Minnesota and continued store expansion (12 new locations). Q4 alone hit $311 million, up 5.7% from the prior year — the company's strongest quarter ever. That said, management guided for a mid-single-digit sequential decline in Q1 2026 due to pricing pressure and seasonality, signaling the growth pace isn't accelerating.

**Margins are compressing, and that's the real story.** Gross margin fell to 48.9% in FY2025 from 52.9% in FY2024. The culprit is pricing pressure across mature state markets — Illinois revenue is declining, wholesale prices are dropping, and promotional activity (customer discounts hit $324 million in FY2025, up from $267 million) is eating into unit economics. SG&A also rose, climbing to $437 million (37.2% of revenue) from $377 million (33.1%) the prior year, driven by new store openings and compensation costs. Operating income fell to $138 million from $224 million. This isn't a crisis — it's the cost of expanding into new markets during an industry downturn. But it means the operating margin story is moving in the wrong direction.

**280E: The $92 million annual tax that shouldn't exist.** Here's where cannabis accounting gets distorted. Green Thumb reported $263 million in pretax income in FY2025 and paid $147 million in income taxes — an effective rate of 55.9%. A normal corporation with that pretax income would pay roughly $55 million at a 21% rate. The difference — approximately $92 million — is the annual cost of Section 280E, which prevents cannabis companies from deducting ordinary business expenses because they traffic in a Schedule I substance. This single line item is the most important number in the entire filing. It's the reason Green Thumb reported $114 million in net income instead of $206 million. It's the reason the P/E looks like 14 times instead of under 8 times. And it's the first thing that changes if rescheduling happens.

Notably, the effective tax rate has actually trended *down* over the past five years — from a peak of 87.4% in FY2022 (when pretax income was compressed) to 55.9% today. That improvement reflects management's discipline in structuring COGS to maximize allowable deductions under 280E. But 56% is still more than double what any normal business pays.

**Cash flow is the real health indicator.** Green Thumb generated $295 million in operating cash flow in FY2025, up 51% from $195 million the year prior. Capital expenditures were $81 million, producing free cash flow of approximately $214 million — the best in the company's history. This matters because GAAP earnings in cannabis are distorted by 280E's non-cash deferred tax accruals, impairments, and depreciation. Cash flow tells the real story: this is a company generating meaningful cash from operations, and the trajectory is accelerating.

**Balance sheet: Net cash, minimal leverage.** Green Thumb ended FY2025 with $274 million in cash (or $285 million including restricted cash) against $245 million in total debt — a net cash position of roughly $29 million. That's the cleanest balance sheet among Tier 1 MSOs. By comparison, Trulieve carries $508 million in debt and Curaleaf holds $967 million. Interest expense was $20 million, comfortably covered by operating cash flow at over 14 times. The company also repurchased $38.9 million in shares during FY2025 and $122 million since September 2023, underscoring management's confidence in the valuation.

**Goodwill: $592 million still on the books.** Green Thumb wrote off $88.5 million in goodwill in FY2022 during the post-boom reckoning. Since then, goodwill has remained essentially stable at roughly $590 million, representing 21% of total assets. Intangible assets add another $437 million. Together, goodwill and intangibles total $1.03 billion against $2.79 billion in total assets — about 37%. That's a significant concentration but manageable given the underlying cash flow generation. No additional impairments have been taken since 2022, suggesting management believes the underlying businesses are performing at or above acquisition-era expectations.

## 4. Catalyst Scenarios — How the Math Changes

**280E relief: The most immediate and quantifiable catalyst.** If marijuana is rescheduled to Schedule III, Section 280E would no longer apply. Using FY2025 numbers: pretax income was $263 million. At a normalized 21% tax rate, income tax expense would be approximately $55 million, yielding adjusted net income of roughly $208 million — compared to $114 million as reported. That's an 82% increase in earnings without growing revenue by a single dollar. Adjusted EPS would jump from $0.48 to approximately $0.88 on 237 million diluted shares. At the current stock price of $6.67, that implies a forward P/E of just 7.6 times adjusted earnings. For a company growing revenue, generating $214 million in free cash flow, and holding a net cash position — that's an unusually low multiple by any sector standard.

**Interstate commerce: GTI's 14-state footprint becomes a national distribution network.** If a Bondi memo or other federal guidance opens the door to interstate commerce between legal states, the entire MSO model shifts from state-by-state vertical integration to national brand distribution. Green Thumb is well-positioned for this scenario. It operates cultivation and manufacturing in 14 states with 20 facilities. The RYTHM brand — already the number-one flower brand nationally despite being sold through fragmented state markets — could scale rapidly across new distribution channels. The CPG segment (29% of revenue) would benefit most, as wholesale product could flow to retail channels in states where GTI doesn't currently hold licenses. The risk here is that interstate commerce also enables low-cost cultivators (e.g., California outdoor growers) to flood eastern markets with cheaper product, compressing wholesale margins further.

**Uplisting: Institutional capital finally has a way in.** With rescheduling, NYSE/NASDAQ listing becomes theoretically possible — though the exchanges have signaled that Schedule III alone may not be sufficient for plant-touching companies. If uplisting happens, the demand dynamics change dramatically. Most institutional funds cannot hold OTC securities. ETF inclusion becomes possible. Analyst coverage follows. For a company with clean financials, GAAP profitability, and a net cash balance sheet, Green Thumb would be among the first MSOs to attract institutional capital. Its consistent profitability and share buyback program signal the kind of capital discipline that institutional investors prioritize.

**Consolidation: Buyer, not target.** Green Thumb's balance sheet — $274 million in cash, $245 million in debt, $214 million in free cash flow — gives it the capacity to be an acquirer. The company has already demonstrated this discipline, executing tuck-in deals while maintaining leverage well below peers. In a post-rescheduling environment where weaker operators face refinancing walls and capital constraints, GTI has the financial flexibility to pick up assets at distressed valuations. The $50 million credit facility expansion announced in 2025 adds further capacity. Enterprise value of $1.53 billion against an asset base of $2.79 billion means GTI is not likely to be a cheap acquisition target — which makes it a potential buyer in a consolidation wave.

**Medicare CBD pilot: Small upside.** The April 2026 Medicare reimbursement pilot ($500/year per beneficiary for physician-recommended CBD products) could eventually benefit GTI's wellness brands (Doctor Solomon's), but this is early-stage and not a material driver in the near term.

## 5. Risks and Open Questions

Rescheduling could stall indefinitely. The DEA has no administrative law judge, the AG has gone silent, and 48 GOP lawmakers publicly oppose rescheduling. The executive order instructs the process to be completed but doesn't guarantee it. If rescheduling is delayed into 2027 or beyond, GTI continues paying $92 million per year in excess taxes with no relief.

Margin compression is a real and present problem. Gross margin fell 400 basis points in FY2025 and SG&A rose as a percentage of revenue. If pricing pressure continues in Illinois (Green Thumb's largest market, where statewide cannabis revenue fell 13% in 2025), operating income could decline further even as top-line revenue grows. Comparable store sales declined 1.8% in Q4, signaling organic growth is under pressure.

The November 2026 hemp product restriction creates uncertainty. New rules limiting THC content to 0.4mg per container would wipe out most hemp-derived products. This could help dispensary operators by eliminating low-cost unregulated competition, but it could also impact GTI's own hemp-adjacent product lines and the broader consumer adoption trend.

## 6. The Bottom Line

Green Thumb Industries is the most consistently profitable public cannabis company in the United States. It generates $1.18 billion in revenue, $295 million in operating cash flow, and $114 million in net income — all while paying a 56% effective tax rate that costs it $92 million a year. If 280E relief comes through rescheduling, adjusted earnings nearly double to $208 million, and the stock trades at under 8 times those adjusted earnings. If it doesn't, Green Thumb still has a net cash balance sheet, $214 million in free cash flow, and a management team that's been buying back shares aggressively. The bull case is a repriced stock in a repriced sector. The bear case is a well-run company in a broken regulatory environment that continues grinding forward. Watch the DEA rulemaking calendar, watch Illinois revenue trends, and watch whether the Bondi memo materializes. The data is all here — what you do with it is your call.